Abstract
Objective
To investigated whether erythropoietin (EPO) would promote the proliferation of human cancer cell line MCF-7, Panc-1 and HepG2 so as to determine whether EPO would result a worse prognosis to the patients with malignant diseases.
Methods
We examined the growth inhibitory or promotional effect of EPO to MCF-7, Panc-1 and HepG2 by MTT assay. Then we examined the cell cycle of those cancer cell lines which was cultured with EPO and without EPO by FCM.
Results
The results showed there was no significant growth inhibitory or promotional effect of EPO to MCF-7, Panc-1 and HepG2. The cell cycle of those cancer cell lines cultured with EPO also has no significant different to that of those cancer cell lines cultured without EPO.
Conclusion
It is concluded that EPO has no promotion effect to the cancer cell lines’ proliferation, and maybe will not result a worse prognosis to the patients with malignant diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cvetkovic RS, Goa KL. Darbepoetin alfa: in patients with chemotherapy-related anaemia. Drugs, 2003, 63: 1067–1074.
Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet, 2003, 362: 1255–1260.
Gordon MS. Managing anemia in the cancer patient: old problems, future solutions. Oncologist, 2002, 7: 331–341.
Maeda Y, Sakaguchi M, Naiki Y, et al. Possible involvement of soluble erythropoietin receptor in resistance to erythropoietin in patients with renal anemia. Am J Nephrol, 2001, 21: 426.
Lappin T. The cellular biology of erythropoietin receptors. Oncologist, 2003, 8Suppl 1: 15–18.
Itri LM. Managing cancer related anaemia with epoetin alfa. Nephrol Dial Transplant, 2002, 17Suppl 1: 73–77.
Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol, 2001, 19: 4126–4134.
Glaspy J, Degos L, Dicato M, et al. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum-and nonplatinumbased chemotherapy: a retrospective subanalysis of two large, community based trials. Oncologist, 2002, 7: 126–135.
Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol, 2006, 24: 4708–4713.
Temkin SM, Hellmann M, Serur E, et al. Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gynecol Cancer, 2006, 16: 1855–1861.
Hardee ME, Rabbani ZN, Arcasoy MO, et al. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther, 2006, 5: 356–361.
Ribatti D, Marzullo A, Nico B, et al. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology, 2003, 42: 246–250.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by a grant from the National Natural Science Foundation of China (No. 30571798).
Rights and permissions
About this article
Cite this article
He, W., Huang, T., Ren, J. et al. The effect of erythropoietin to the proliferation of cancer cell lines. Chin. -Ger. J. Clin. Oncol. 7, 361–364 (2008). https://doi.org/10.1007/s10330-008-0007-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-008-0007-1